The novel antibodies salivary gland protein 1 (SP-1), carbonic anhydrase 6 (CA VI) and parotid secretory protein (PSP) have shown to be present in animal models for Sjogren's syndrome (SS) and patients with the disease. The antibodies SP-1, CA VI and PSP occurred earlier in the course of the disease than antibodies to Ro or La. These antibodies were found in 45% of patients meeting the criteria for SS who lacked antibodies to Ro or La. Furthermore, in patients with idiopathic xerostomia and xerophthalmia for less than 2 years, 76% had antibodies to SP-1 and/or CA VI while only 31% had antibodies to Ro or La. Antibodies to SP-1, CA VI and PSP may be useful markers for identifying patients with SS at early stages of the disease or those that lack antibodies to either Ro or La. The presence of the antibodies to SP-1, CA VI and PSP should be correlated with clinical (dry mouth, dry eyes), serological (Ro, La,
ANA, RF) and histological (positive lymphocytic focus scores) findings in establishing a definitive diagnosis for SS.
References:
- Shen, L. et al. (2010). A role of lymphotoxin in primary sjogren's syndrome. J Immunol; 185: 6355-6363. [L]
- Shen, L. et al. (2012). Novel autoantibodies in Sjogren's syndrome. Clinical Immunology; 145, 251-255. [L]
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.